The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 301–400 of 1,003
Absolute lymphocyte count predicts overall survival in follicular lymphomas
Siddiqui, M. A., Ristow, K. M., Markovic, S. N., Witzig, T. E., Habermann, T. M., Colgan, J. P., Inwards, D. J., White, W. L., Ansell, S. M., Micallef, I. N., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06232.x · Cited by 109
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
Jubb, A. M., Turley, H., Moeller, H. C., Steers, G., Han, C., Li, J., Leek, R., Tan, E. Y., Singh, B., Mortensen, N., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605368 · Cited by 113
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Butterfield, L. H., Palucka, A. K., Britten, C. M., Dhodapkar, M. V., Håkansson, L., Janetzki, S., Kawakami, Y., Kleen, T. O., Lee, P. P., Maccalli, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2234 · Cited by 107
In situ validation of an intestinal stem cell signature in colorectal cancer
Ziskin, J. L., Dunlap, D. Y., Yaylaoglu, M., Fodor, I. K., Forrest, W. F., Patel, R., Ge, N., Hutchins, G. G. A., Pine, J. K., Quirke, P., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301195 · Cited by 108
Umar, A., Kang, H., Timmermans, A. M., Look, M. P., Gelder, M. E. M., den Bakker, M. A., Jaitly, N., Martens, J. W. M., Luider, T. M., Foekens, J. A., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800493-mcp200 · Cited by 108
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
Jeannot, E., Latouche, A., Bonneau, C., Calméjane, M.-A., Beaufort, C. M., Ruigrok-Ritstier, K., Bataillon, G., Chérif, L. L., Dupain, C., Lecerf, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0625 · Cited by 108
Rahnenführer, J., Bin, R. D., Benner, A., Ambrogi, F., Lusa, L., Boulesteix, A., Migliavacca, E., Binder, H., Michiels, S., Sauerbrei, W., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02858-y · Cited by 132
Self-citationSerum cell‐free DNA in renal cell carcinoma
de Martino, M., Klatte, T., Haitel, A., & Marberger, M. (2011) · Cancer · doi:10.1002/cncr.26254 · Cited by 108
Payne, S. R., Serth, J., Schostak, M., Kamradt, J., Strauß, A., Thelen, P., Model, F., Day, J., Liebenberg, V., Morotti, A., et al. (2009) · The Prostate · doi:10.1002/pros.20967 · Cited by 108
Ansari, D., Rosendahl, A. H., Elebro, J., & Andersson, R. E. (2011) · British journal of surgery · doi:10.1002/bjs.7574 · Cited by 107
Li, H., Liu, J., Chen, J., Wang, H., Yang, L., Chen, F., Fan, S., Wang, J., Shao, B., Yin, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03537-w · Cited by 107
Pirozzolo, G., Gisbertz, S., Castoro, C., Henegouwen, M. I. V. B., & Scarpa, M. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.07.30 · Cited by 91
An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma
Ács, B., Ahmed, F. S., Gupta, S., Wong, P. F., Gartrell, R. D., Pradhan, J. S., Rizk, E. M., Rothberg, B. G., Saenger, Y. M., & Rimm, D. L. (2019) · Nature Communications · doi:10.1038/s41467-019-13043-2 · Cited by 105
Karlsen, M. A., Høgdall, E. V. S., Christensen, I. J., Borgfeldt, C., Kalapotharakos, G., Dubská, L. Z., Chovanec, J., Lok, C. A. R., Stiekema, A., Mutz‐Dehbalaie, I., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.021 · Cited by 107
Inflammatory Biomarkers and Bladder Cancer Prognosis: A Systematic Review
Masson-Lecomte, A., Rava, M., Real, F. X., Hartmann, A., Allory, Y., & Malats, N. (2014) · European Urology · doi:10.1016/j.eururo.2014.07.033 · Cited by 109
Prognostic value of PDL1 expression in pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Turrini, O., Raoul, J., Delpéro, J., Moutardier, V., Birnbaum, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11685 · Cited by 108
Craig, S. G., Anderson, L. A., Schache, A. G., Moran, M., Graham, L., Currie, K., Rooney, K. P., Robinson, M., Upile, N. S., Brooker, R. C., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0414-9 · Cited by 106
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer
Lotan, Y., Shariat, S. F., Schmitz‐Dräger, B. J., Sänchez‐Carbayo, M., Jankevičius, F., Racioppi, M., Minner, S. J. P., Stöhr, B., Bassi, P. F., & Grossman, H. B. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.11.004 · Cited by 105
Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer
Effenberger, K. E., Schroeder, C., Hanssen, A., Wolter, S., zu Eulenburg, C., Tachezy, M., Gebauer, F., Izbicki, J. R., Pantel, K., & Bockhorn, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0120 · Cited by 105
Weiner, A. B., Vidotto, T., Liu, Y., Mendes, A. A. D. A., Salles, D. C., Faisal, F. A., Murali, S., McFarlane, M., Imada, E. L., Zhao, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21245-w · Cited by 108
Unique Localization of Circulating Tumor Cells in Patients With Hepatic Metastases
Jiao, L. R., Apostolopoulos, C., Jacob, J., Szydlo, R., Johnson, N., Tsim, N., Habib, N. A., Coombes, R. C., & Stebbing, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5837 · Cited by 105
microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis
Frampton, A. E., Krell, J., Jamieson, N. B., Gall, T., Giovannetti, E., Funel, N., Prado, M. M., Krell, D., Habib, N., Castellano, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.006 · Cited by 106
Diagnosis of malignant glioma: role of neuropathology
Brat, D. J., Prayson, R. A., Ryken, T. C., & Olson, J. J. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9618-1 · Cited by 107
Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer
Smerage, J. B., Budd, G. T., Doyle, G. V., Brown, M., Paoletti, C., Muñiz, M. C., Miller, M. C., Repollet, M., Chianese, D. A., Connelly, M. C., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.013 · Cited by 103
Rakaee, M., Kilvaer, T. K., Jamaly, S., Berg, T., Paulsen, E., Berglund, M., Richardsen, E. H., Andersen, S., Al‐Saad, S., Poehl, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01307-y · Cited by 108
Miller, W. R., Larionov, A. A., Renshaw, L., Anderson, T. J., Walker, J. R., Krause, A., Sing, T., Evans, D. B., & Dixon, J. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8849 · Cited by 102
Waidmann, O., Brunner, F., Herrmann, E. M., Zeuzem, S., Piiper, A., & Kronenberger, B. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.005 · Cited by 102
Frantzi, M., van Kessel, K. E., Zwarthoff, E. C., Márquez, M., Rava, M., Malats, N., Merseburger, A. S., Katafigiotis, I. S., STRAVODIMOS, K. G., Mullen, W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2715 · Cited by 102
Aleskandarany, M. A., Abduljabbar, R. F., Ashankyty, I., Elmouna, A., Jerjees, D. A., Ali, S., Buluwela, L., Diez, M., Caldas, C., Green, A. R., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3934-5 · Cited by 101
The challenges of gene expression microarrays for the study of human cancer
Tinker, A. V., Boussioutas, A., & Bowtell, D. D. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.001 · Cited by 103
Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S. M. A., Tomaszewski, J. M., Verschoor, S., Millar, E. K. A., van der Spek, P. J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2814 · Cited by 103
den Eynden, G. G. V., Vandenberghe, M., van Dam, P.-J. H., Colpaert, C., van Dam, P. A., Dirix, L. Y., Vermeulen, P. B., & Marck, E. A. V. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1230 · Cited by 102
Bostner, J., Karlsson, E. A., Pandiyan, M. J., Westman, H., Skoog, L. K., Fornander, T., Nordenskjöld, B. A., & Stål, O. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2376-y · Cited by 102
Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer
Malinowsky, K., Nitsche, U., Janssen, K., Bader, F. G., Späth, C., Drecoll, E., Keller, G., Höfler, H., Slotta‐Huspenina, J., & Becker, K.-F. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.100 · Cited by 101
The prognostic impact of age in different molecular subtypes of breast cancer
Liedtke, C., Rody, A., Gluz, O., Baumann, K., Beyer, D. A., Kohls, E.-B., Lausen, K., Hanker, L., Holtrich, U., Becker, S., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3491-3 · Cited by 100
Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy
Sultana, R., Abdel-Fatah, T. M. A., Abbotts, R., Hawkes, C., Albarakati, N., Seedhouse, C., Ball, G., Chan, S. Y. T., Rakha, E. A., Ellis, I. O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2929 · Cited by 100
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Miller, L. D., Chou, J., Black, M. A., Print, C. G., Chifman, J., Alistar, A. T., Putti, T. C., Zhou, X., Bedognetti, D., Hendrickx, W., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0149 · Cited by 101
Yerushalmi, R., Tyldesley, S. K., Kennecke, H. F., Speers, C. H., Woods, R. R., Knight, B., & Gelmon, K. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr154 · Cited by 100
Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer
Chen, M., Huang, J., Zhu, Z., Zhang, J., & Li, K. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-539 · Cited by 99
Shigaki, H., Baba, Y., Watanabe, M., Murata, A., Iwagami, S., Miyake, K., Ishimoto, T., Iwatsuki, M., & Baba, H. (2012) · Gastric Cancer · doi:10.1007/s10120-012-0209-7 · Cited by 100
Abdel-Fatah, T. M. A., Agarwal, D., Liu, D., Russell, R., Rueda, O. M., Liu, K., Xu, B., Moseley, P. M., Green, A. R., Pockley, A. G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00174-1 · Cited by 118
Tang, Z., & Ma, Z. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.06.041 · Cited by 99
Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology
Webster, J. D., Dennis, M. M., Dervisis, N. G., Heller, J., Bacon, N. J., Bergman, P. J., Bienzle, D., Cassali, G. D., Castagnaro, M., Cullen, J. M., et al. (2010) · Veterinary Pathology · doi:10.1177/0300985810377187 · Cited by 100
SIRT2: Tumour suppressor or tumour promoter in operable breast cancer?
McGlynn, L. M., Zino, S., Macdonald, A. I., Curle, J., Reilly, J. E., Mohammed, Z. M. A., McMillan, D. C., Mallon, E., Payne, A. P., Edwards, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.10.005 · Cited by 99
Daskalaki, A., Agelaki, S., Perraki, M., Apostolaki, S., Xenidis, N., Stathopoulos, E., Kontopodis, E., Hatzidaki, D., Mavroudis, D., & Georgoulias, V. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605183 · Cited by 98
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Schneider, B. P., Shen, F., Gardner, L., Radovich, M., Li, L., Miller, K. D., Jiang, G., Lai, D., O’Neill, A., Sparano, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0908 · Cited by 98
Prognostic impact of FOXP3 expression in triple-negative breast cancer
Lee, S. H., Cho, E. Y., Park, Y. H., Ahn, J. S., & Im, Y. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.731520 · Cited by 98
Keratin-17 Promotes p27KIP1 Nuclear Export and Degradation and Offers Potential Prognostic Utility
Escobar‐Hoyos, L. F., Shah, R., Roa‐Peña, L., Vanner, E. A., Najafian, N., Banach, A., Nielsen, E., Al-Khalil, R., Akalin, A., Talmage, D. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0293 · Cited by 98
An empirical assessment of validation practices for molecular classifiers
Castaldi, P. J., Dahabreh, I. J., & Ioannidis, J. P. A. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbq073 · Cited by 101
Bernstein, J. M., Homer, J. J., & West, C. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.07.011 · Cited by 97
Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer
Parkinson, D. R., Mccormack, R. T., Keating, S. M., Gutman, S. I., Hamilton, S. R., Mansfield, E. A., Piper, M., Deverka, P. A., Frueh, F. W., Jessup, J. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2961 · Cited by 101
Self-citationLi, B., Chonghaile, T. N., Fan, Y., Madden, S. F., Klinger, R. W., O’Connor, A. E., Walsh, L., O’Hurley, G., Udupi, G. M., Joseph, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2546 · Cited by 97
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Jubb, A. M., Miller, K. D., Rugo, H. S., Harris, A. L., Chen, D., Reimann, J. D., Cobleigh, M., Schmidt, M., Langmuir, V. K., Hillan, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1791 · Cited by 101
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
Ong, F. S.-C., Das, K., Wang, J., Vakil, H., Kuo, J., Blackwell, W.-L. B., Lim, S. W., Goodarzi, M. O., Bernstein, K. E., Rotter, J. I., et al. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.59 · Cited by 96
Salivary biomarkers in the diagnosis of breast cancer: A review
Mascarenhas, E. C. P., Assad, D. X., Chardin, H., Gozal, D., Canto, G. D. L., Acevedo, A. C., & Guerra, E. N. S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.009 · Cited by 98
Paulsen, E., Kilvaer, T. K., Rakaee, M., Richardsen, E. H., Hald, S. M., Andersen, S., Busund, L., Bremnes, R. M., & Dønnem, T. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2039-2 · Cited by 102
Smid, M., Hoes, M., Sieuwerts, A. M., Sleijfer, S., Zhang, Y., Wang, Y., Foekens, J. A., & Martens, J. W. M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1026-5 · Cited by 96
High tumor budding stratifies breast cancer with metastatic properties
Salhia, B., Trippel, M. A., Pfaltz, K., Čihorić, N., Grogg, A., Lädrach, C., Zlobec, I., & Tapia, C. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3333-3 · Cited by 96
Liu, N. Q., Stingl, C., Look, M. P., Smid, M., Braakman, R. B. H., Marchi, T. D., Sieuwerts, A. M., Span, P. N., Sweep, F. C. G. J., Linderholm, B. K., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt376 · Cited by 96
Zhang, L., Li, J., Xiao, Y., Cui, H., Du, G., Wang, Y., Li, Z., Wu, T., Li, X., & Tian, J. (2015) · Scientific Reports · doi:10.1038/srep11085 · Cited by 96
A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer
Ahmed, M. A. H., Aleskandarany, M. A., Rakha, E. A., Moustafa, R. Z. A., Benhasouna, A., Nolan, C. C., Green, A. R., Ilyas, M., & Ellis, I. O. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1865-8 · Cited by 95
Moreau, S., Saïag, P., Aegerter, P., Bosset, D., Longvert, C., Hélias‐Rodzewicz, Z., Marin, C., Peschaud, F., Chagnon, S., Zimmermann, U., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2457-5 · Cited by 95
Schmitt, M., Harbeck, N., Brünner, N., Jänicke, F., Meisner, C., Muehlenweg, B., Jansen, H., Dorn, J., Nitz, U. A., Kantelhardt, E. J., et al. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.47 · Cited by 95
TIMP-1 as a tumor marker in breast cancer – An update
Würtz, S. Ø., Würtz, S. Ø., Schrohl, A., Mouridsen, H. T., & Brünner, N. (2008) · Acta Oncologica · doi:10.1080/02841860802022976 · Cited by 95
Tandon, S., Smith, C. T., Riley, R. D., Boyd, M. T., & Jones, T. M. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0981 · Cited by 95
Bartlett, J. M. S., Munro, A. F., Cameron, D., Thomas, J. S. J., Prescott, R. J., & Twelves, C. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6597 · Cited by 95
Meyer, S., Fuchs, T. J., Bosserhoff, A., Hofstädter, F., Pauer, A., Röth, V., Buhmann, J. M., Moll, I., Anagnostou, N., Brandner, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038222 · Cited by 94
Shigaki, H., Baba, Y., Watanabe, M., Murata, A., Ishimoto, T., Iwatsuki, M., Iwagami, S., Nosho, K., & Baba, H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3559 · Cited by 99
Rothberg, B. E. G., & Bracken, M. B. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9248-2 · Cited by 95
Kyzas, P., Denaxa-Kyza, D., & Ioannidis, J. (2007) · Journal of the National Cancer Institute · doi:10.1093/jnci/djk032 · Cited by 95
Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment
Pories, S. E., Zurakowski, D., Roy, R., Lamb, C. C., Raza, S., Exarhopoulos, A., Scheib, R. G., Schumer, S., Lenahan, C., Borges, V. F., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0365 · Cited by 94
Hoshimoto, S., Faries, M. B., Morton, D. L., Shingai, T., Kuo, C. T., Wang, H. J., Elashoff, R. M., Mozzillo, N., Kelley, M. C., Thompson, J. F., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182380f56 · Cited by 93
Abraham, J., Maranian, M. J., Driver, K. E., Platte, R., Kalmyrzaev, B., Baynes, C., Luccarini, C., Shah, M., Ingle, S., Greenberg, D. C., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2629 · Cited by 93
QUAPAS: An Adaptation of the QUADAS-2 Tool to Assess Prognostic Accuracy Studies
Lee, J., Mulder, F. I., Leeflang, M., Wolff, R. F., Whiting, P. F., & Bossuyt, P. M. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0276 · Cited by 102
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
Ferté, C., André, F., & Soria, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.84 · Cited by 96
Okines, A. F. C., Thompson, L. C., Cunningham, D., Wotherspoon, A. C., Reis-Filho, J. S., Langley, R. E., Waddell, T. S., Noor, D., Eltahir, Z., Wong, R., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds622 · Cited by 93
Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer
Zhang, Y., Martens, J. W. M., Yu, J. X., Jiang, J., Sieuwerts, A. M., Smid, M., Klijn, J. G. M., Wang, Y., & Foekens, J. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4596 · Cited by 93
Uemura, M., Yamamoto, H., Takemasa, I., Mimori, K., Hemmi, H., Mizushima, T., Ikeda, M., Sekimoto, M., Matsuura∥, N., Doki, Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0407 · Cited by 92
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment
Westbrook, J. A., Cairns, D. A., Peng, J., Speirs, V., Hanby, A. M., Holen, I., Wood, S. L., Ottewell, P. D., Marshall, H. C., Banks, R. E., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv360 · Cited by 92
Liang, C., Lee, Y. H., Thein, T.-L., Fang, J., Pang, J., Ooi, E. E., Leo, Y., Ong, C. N., & Tannenbaum, S. R. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004607 · Cited by 93
Pavón, M. Á., Arroyo‐Solera, I., Tellez-Gabriel, M., León, X., Porcuna, D. V., López, M., Gallardo, A., Céspedes, M. V., Casanova, I., Pousa, A. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5032 · Cited by 94
Koopman, M., Venderbosch, S., van Tinteren, H., Ligtenberg, M. J. L., Nagtegaal, I. D., van Krieken, J. H., & Punt, C. J. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.017 · Cited by 91
The Importance of Identifying and Validating Prognostic Factors in Oncology
Halabi, S., & Owzar, K. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.04.001 · Cited by 91
Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms
Rothberg, B. E. G., Berger, A. J., Molinaro, A. M., Subtil, A., Krauthammer, M. O., Camp, R. L., Bradley, W. R., Ariyan, S., Kluger, H. M., & Rimm, D. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8239 · Cited by 91
Correale, P., Rotundo, M. S., Botta, C., Vecchio, M. T. D., Ginanneschi, C., Licchetta, A., Conca, R., Apollinari, S., Luca, F. D., Tassone, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3186 · Cited by 91
Ptolemy, A. S., & Rifai, N. (2010) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2010.493354 · Cited by 90
Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma
Cho, E. J., Leem, S., Kim, S. A., Yang, J., Lee, Y. B., Kim, S. S., Cheong, J. Y., Cho, S. W., Kim, J. W., Kim, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44012-w · Cited by 94
Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer
Bhawal, R. P., Oberg, A. L., Zhang, S., & Kohli, M. (2020) · Cancers · doi:10.3390/cancers12092428 · Cited by 92
TRIPOD statement: a preliminary pre-post analysis of reporting and methods of prediction models
Najafabadi, A. H. Z., Ramspek, C. L., Dekker, F. W., Heus, P., Hooft, L., Moons, K. G. M., Peul, W. C., Collins, P. G. S., Steyerberg, E. W., & van Diepen, M. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041537 · Cited by 93
Shaping the future of biomarker research in breast cancer to ensure clinical relevance
Hinestrosa, M. C., Dickersin, K., Klein, P. M., Mayer, M., Noss, K., Slamon, D. J., Sledge, G. W., & Visco, F. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2113 · Cited by 92
Schultz, N. A., Andersen, K. K., Roslind, A., Willenbrock, H., Wøjdemann, M., & Johansen, J. S. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1705-y · Cited by 89
Identification of Evidence-Based Biospecimen Quality-Control Tools
Betsou, F., Gunter, E. W., Clements, J. A., DeSouza, Y., Goddard, K. A. B., Guadagni, F., Yan, W., Skubitz, A. P. N., Somiari, S., Yeadon, T. M., et al. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.06.008 · Cited by 89
Sparano, J. A., Gray, R. J., Oktay, M. H., Entenberg, D. R., Rohan, T. E., Xue, X., Donovan, M., Peterson, M., Shuber, A. P., Hamilton, D. A., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0043-5 · Cited by 89
Finkelmeier, F., Kronenberger, B., Köberle, V., Bojunga, J., Zeuzem, S., Trojan, J., Piiper, A., & Waidmann, O. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12731 · Cited by 89
Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement
Janssens, A. C. J. W., Ioannidis, J. P. A., van Duijn, C. M., Little, J., Khoury, M. J., & for the GRIPS Group (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000420 · Cited by 87
Kiyozumi, Y., Baba, Y., Okadome, K., Yagi, T., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., Komohara, Y., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002754 · Cited by 88
Prognostic significance of 8-hydroxy-2′-deoxyguanosine in solid tumors: a meta-analysis
Qing, X., Shi, D., Lv, X., Wang, B., Chen, S., & Shao, Z. (2019) · BMC Cancer · doi:10.1186/s12885-019-6189-9 · Cited by 92
Lee, C., Chang, Y.-C., Chen, C.-S., Tu, S., Wang, Y., Chen, L.-C., Chang, Y., Wei, P., Chang, H.-W., Chang, C.-H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1209-0 · Cited by 90
Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach
Paulsen, E., Kilvaer, T. K., Rakaee, M., Al‐Saad, S., Hald, S. M., Andersen, S., Richardsen, E. H., Ness, N., Busund, L., Bremnes, R. M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.009 · Cited by 87
Phenotype of POLE-mutated endometrial cancer
Imboden, S., Nastic, D., Ghaderi, M., Rydberg, F., Rau, T. T., Mueller, M. D., Epstein, E., & Carlson, J. W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214318 · Cited by 88
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
